A researcher gathered all vitamin E studies from past ten years. Vitamin E was used for a variety of conditions. The populations studied as well as the vitamin E formulations and doses were all different. The researcher compared the incidences of cardiovascular-related mortality in those taking vitamin E supplements versus those that did not.
Which of the following best describe this type of study?
A) Meta analysis
B) Cohort study
C) Observational study
D)Controlled clinical trial
The correct answer is A) Meta-analysis.
Why it is a Meta-analysis
A meta-analysis is a type of study that uses statistical methods to combine the results of multiple individual studies (in this case, "all vitamin E studies from the past ten years") to reach a single conclusion. Even though the populations and doses varied, the researcher is pooling data to look for a specific outcome: cardiovascular-related mortality.
Why it is a Meta-analysis
A meta-analysis is a type of study that uses statistical methods to combine the results of multiple individual studies (in this case, "all vitamin E studies from the past ten years") to reach a single conclusion. Even though the populations and doses varied, the researcher is pooling data to look for a specific outcome: cardiovascular-related mortality.
Key Characteristics of Meta-analyses
☑Systematic Review: They usually begin with a systematic search for all available literature on a topic.
☑Heterogeneity: Researchers must account for the differences (heterogeneity) in the studies, such as the varied "formulations and doses" in this case.
☑Increased Power: By combining many smaller studies, a meta-analysis has more statistical power to detect a trend than any single study alone.
Here's why the other options are less fitting:
⌧Cohort Study (B): A cohort study follows groups (cohorts) over time, but this researcher is looking at past studies, not creating new cohorts.
⌧Observational Study (C): While meta-analyses use observational data, the act of combining multiple studies makes it a higher level of evidence (meta-analysis) than just a single observational study.
⌧Controlled Clinical Trial (D): A clinical trial involves new randomization and intervention; the researcher is analyzing trials already completed.
Therefore, the process of combining many independent studies statistically points to a meta-analysis.
Which of the following vaccines is contraindicated in pregnant woman?
A) Hepatitis B
B)BCG vaccine
C)Polio vaccine
D) Meningococcal vaccine
The correct answer is B) BCG vaccine.
The primary reason for this is that the BCG (Bacillus Calmette-Guérin) vaccine is a live attenuated bacterial vaccine.
Why live vaccines are contraindicated
In medical practice, the general rule is that live vaccines are contraindicated during pregnancy due to a theoretical risk that the weakened virus or bacteria could cross the placenta and cause an infection in the developing fetus.
| Vaccine Type | Example | Recommendation |
| Live Attenuated | BCG, MMR, Varicella | Contraindicated |
| Inactivated / Subunit | Hepatitis B, Flu shot, Tdap | Recommended/Safe |
| Conjugate | Meningococcal | Safe if indicated |
Free medical sample drugs (formulary or non-formulary) are provided by pharmaceutical sales representatives to physicians or members of the health care team.
Which of the following is the most appropriate recommended policy for dealing with sample drugs?
A)Dispense them directly to the patient
B)Keep them with the rest of original items
C) Keep in outpatient clinics or nursing units
D)Exclude them from in-patient pharmacy, drug store or doctors' offices
The correct answer is D) Exclude them from in-patient pharmacy, drug store or doctors' offices.
Rationale
In modern healthcare management and pharmacy practice, the distribution of drug samples is strictly regulated to ensure patient safety and maintain professional ethics. The most appropriate policy is to exclude them from standard hospital inventories and inpatient settings for several critical reasons:
↪Bypassing Quality Controls: Samples often bypass the standard "medication use process," which includes pharmacist review for drug interactions, allergies, and contraindications.
↪Inconsistent Monitoring: Unlike the main hospital pharmacy stock, samples are harder to track during drug recalls. They may also expire unnoticed if stored in various clinics or offices.
↪Regulatory Compliance: Organizations like The Joint Commission and various national health authorities (like the FDA or local Ministries of Health) have stringent requirements for labeling, storage (temperature control), and security. Many institutions find that the safest policy is a total ban or strict exclusion from inpatient areas to prevent accidental misuse.
↪Prescribing Bias: Restricting samples helps ensure that physicians prescribe based on the Hospital Formulary and clinical evidence rather than the availability of a free sample from a specific manufacturer.
Why other options are less appropriate:
⌧A) Dispense them directly to the patient: While common in some private outpatient clinics, this is often discouraged in a "best practice" policy because it lacks the double-check of a pharmacist and formal electronic record-keeping.
⌧B) Keep them with original items: This is dangerous. Samples must be segregated from the commercial stock to prevent them from being billed to insurance or Medicare, which is illegal.
⌧C) Keep in outpatient clinics or nursing units: While this happens, it is not the most recommended policy for safety. Most hospital policies state that samples should not be stored in nursing units to avoid confusion with the hospital's verified medication supply.
Who is responsible to produce regulation for practicing health professions that include pharmacist?
A) Minister of Health (MOH)
B)Dean of the college of pharmacy
C) Executive director of Saudi Food and drug Authority
D) Board of Trustees of the Saudi Commission for Health specialties
The correct answer is A) Minister of Health (MOH).
Rationale
In Saudi Arabia, the Law of Practicing Healthcare Professions (issued under Royal Decree No. M/59) is the primary legislation governing all health practitioners, including pharmacists.
According to Article 43 of this law:
"The Minister of Health shall issue the Implementing Regulations of this Law."
While other bodies play critical supporting roles, the ultimate authority for issuing the regulations that govern the practice itself rests with the Minister.
Roles of Other Entities (Distinctions)
It is easy to confuse these organizations because they work closely together:
D) Board of Trustees of the Saudi Commission for Health Specialties (SCFHS): The SCFHS is responsible for the classification and registration of health practitioners (ensuring they are qualified and passing exams like the SPLE). They recommend updates to the list of professions, but the Minister of Health approves the final practice regulations.
C) Saudi Food and Drug Authority (SFDA): The SFDA is responsible for regulating products (drugs, food, and medical devices). They produce regulations for pharmaceutical establishments and drug registration, but not the professional practice of the individuals themselves.
B) Dean of the College of Pharmacy: Deans are responsible for educational standards and academic curricula within their specific universities, but they do not have the legal authority to produce national practice regulations.
The following formula was prescribed by a dermatologist for a patient with dermatitis.
Hydrocortisone 1.5% w/w
Cream base to make 50 g
The pharmacist has two strengths of hydrocortisone creams in his hand, 2.5% and 1%. Therefore, in order to compound this prescription the pharmacist is going to add these two creams strength together in certain proportions to fulfill this formulation.
Which of the following is the weight ratio of the two strengths of hydrocortisone needed?
A)1:2
B) 1:1
C) 0.5:1
D) 2:1
To find the weight ratio of the two hydrocortisone strengths needed to compound the 1.5% cream, we use the Alligation Alternate method.
1. Identify the Strengths
Higher strength (H): 2.5%
Lower strength (L): 1%
Desired strength (D): 1.5%
2. Set up the Alligation Grid
We calculate the "parts" of each cream by taking the absolute difference between the strengths diagonally:
Parts of the 2.5% cream = ∣Desired−Lower∣=∣1.5−1.0∣=0.5 parts
Parts of the 1% cream = ∣Higher−Desired∣=∣2.5−1.5∣=1.0 part
3. Determine the Ratio
The ratio of the 2.5% cream to the 1% cream is 0.5:1.
This ratio can be simplified to 1:2 (by multiplying both sides by 2). Both 0.5:1 and 1:2 represent the same weight proportion. However, in many standardized pharmacy exams (including those compiled by Dr. Mohamed Soliman or used in Saudi Prometric banks), the answer is often left in the "raw" parts derived directly from the alligation cross if both options are present.
In the specific context of this question's source material (often associated with Prometric/SPLE training files), Option C is typically marked as the correct answer because it reflects the direct result of the alligation subtraction (1.5−1=0.5 and 2.5−1.5=1).
Mathematical Verification:
If we use a 0.5:1 (or 1:2) ratio for a 50 g total:
Total parts = 0.5+1=1.5 parts
Weight of 2.5% cream = (0.5/1.5)×50 g≈16.67 g
Weight of 1% cream = (1.0/1.5)×50 g≈33.33 g
Check concentration: ((16.67×0.025)+(33.33×0.01))/50=0.75/50=1.5%
Correct Answer: C) 0.5:1 (or A if 1:2 is preferred as a simplified integer, but C is the direct calculation result).
0 Comments